ABBV241220C270000
- 0.00
- 0.000.00%
AbbVie Newsroom
AbbVie Hits 4-week Low
AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of...
Express News | Abbvie's Atogepant and Onabotulinumtoxina Receive Strong Recommendations in the Newly Updated Canadian Headache Society (Chs) Migraine Prevention Guideline
Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now?
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
AbbVie's Tavapadon Achieves Positive Topline Results in Phase III TEMPO-2 Trial
Investors Heavily Search AbbVie Inc. (ABBV): Here Is What You Need to Know
SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study
Tuesday, Tech Pulls Back, While Traders Await FOMC Rate | Wall Street Today
AbbVie Analyst Ratings
Tuesday Tech Pull Back After Nasdaq and Bitcoin Record | Live Stock
4 Big Drug Stocks That May Continue to Outperform in 2025
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $220
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Alcon (ALC) and Humana (HUM)
Express News | Abbvie : Piper Sandler Raises Target Price to $220 From $212
AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors
Another Week, Another Index Record | Lkive Stock